Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
OpenAI Restricts Astra AI Over Cyberattack Risks 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
GAITHERSBURG, Md., March 06, 2018 -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at the 30th Annual ROTH Conference and the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium.
| 30th Annual ROTH Conference Presentation Details | ||
| Date: | Tuesday, March 13 | |
| Time: | 7:00pm Eastern Time/4:00pm Pacific Time | |
| Location: | The Ritz Carlton Orange County, Newport Beach, California – Salon 6 | |
| B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) | ||
| Date: | Saturday, March 17 | |
| Time: | 8:30am China Time/7:30pm Eastern Time – Room A | |
| Location: | Intercontinental Hotel, Hangzhou, China | |
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including, NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.
Contacts:
Bill Enright
President and CEO
Phone: 240-654-1450
Email: [email protected]
Ashley Robinson
Managing Director LifeSci Advisors
Phone: 617-535-7742
Email: [email protected]
